Neuroscience researchers have zeroed in on a novel mechanism that helps control the firing of electrical signals among neurons. By isolating the molecular and electrical events that occur when this control is disrupted, the new research sheds light on epileptic seizures and potentially on other prominent diseases involving poorly regulated brain activity.
"By better understanding the detailed events that occur in epilepsy, we are gaining knowledge that could ultimately lead to better treatments for epilepsy, and possibly for other neurological diseases," said neuroscientist Douglas A. Coulter, Ph.D., the corresponding author of the research study, from The Children's Hospital of Philadelphia. "Temporal lobe epilepsy, in particular, often resists current treatments."
Coulter's research group, collaborating with a team led by co-senior author Philip G. Haydon, Ph.D., of Tufts University School of Medicine, published a study online today in the journal Nature Neuroscience.
In epilepsy, excessive signaling between neurons, a major type of brain cell that communicates electrical signals across gaps called synapses, can lead to epileptic seizures. However, another class of brain cells called glia can regulate those signals. Among the glia are star-shaped cells called astrocytes—the particular focus of this research.
"This study shows that changes in astrocytes are key to brain dysfunction and opens the potential for novel therapeutic strategies in epilepsy," said Haydon, the Annetta and Gustav Grisard professor and chair of the department of neuroscience at Tufts.
The researchers focused on an abnormal condition called reactive astrocytosis, known to occur in many neurological diseases. The astrocytes swell to a large size and change expression levels of a number of proteins. The impact of reactive astrocytosis on brain function is difficult to investigate because it usually occurs in the context of brain inflammation and abnormal changes in surrounding cells.
The researchers solved this problem by using a virus to selectively cause reactive astrocytosis without triggering broader inflammation and brain injury, in a mouse model. They were able to focus on how the altered astrocytes affected specific synapses in neurons in the brain's hippocampus.
Studying the neuronal circuitry in brain slices from the mice, the study team found that changes in reactive astrocytes profoundly reduced the inhibitory control over brain signals.
Healthy brain function requires a delicate balance between excitation—the firing of brain signals—and inhibition, which limits those signals. An enzyme called glutamine synthetase is a key actor in a biological cycle that regulates the balance. The current study found that reactive astrocytosis reduces the supply of that enzyme, which in turn decreases inhibition and allows neurons to fire out of control.
"We already know that inhibition is a powerful force in the brain," said Coulter. "In epilepsy, inhibition is not working properly, and uncontrolled signaling leads to epileptic seizures. Because both disrupted inhibition and reactive astrocytosis are known to occur in other neurologic conditions, including many psychiatric disorders, traumatic brain injury, and neurodegenerative disorders such as Parkinson's disease, our findings may have wide implications."
Significantly, the researchers were able to dampen neuronal excitability in the animals' brain slices by adding glutamine, an amino acid that is depleted as a result of reduced glutamine synthetase activity. Coulter's and Haydon's teams are continuing animal studies to further investigate how this research may contribute to developing better treatments for epilepsy.
The National Institute of Neurological Disorders and Stroke and the National Institute of Mental Health, both part of the National Institutes of Health, provided funding support for this study, as did the Epilepsy Foundation. Co-authors with Coulter and Haydon were first authors Pavel I. Ortinski, Ph.D., of Children's Hospital, and Jinghui Dong, Ph.D., of Tufts, as well as Alison Mungenast of Tufts; Cuiyong Yue and Hajime Takano, of Children's Hospital, and Deborah J. Watson of the University of Pennsylvania School of Medicine. Coulter also is on the faculty of the University of Pennsylvania School of Medicine. Haydon is also a member of the neuroscience program faculty at the Sackler School of Graduate Biomedical Sciences at Tufts.
"Selective induction of astrocytic gliosis generates deficits in neuronal inhibition," Nature Neuroscience, published online April 25, 2010. http://dx.doi.org/10.1038/nn.2535
About The Children's Hospital of Philadelphia
The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country, ranking second in National Institutes of Health funding. In addition, its unique family-centered care and public service programs have brought the 460-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu.
About Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences
Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences at Tufts University are international leaders in innovative medical education and advanced research. The School of Medicine and the Sackler School are renowned for excellence in education in general medicine, biomedical sciences, special combined degree programs in business, health management, public health, bioengineering and international relations, as well as basic and clinical research at the cellular and molecular level. Ranked among the top in the nation, the School of Medicine is affiliated with six major teaching hospitals and more than 30 health care facilities. Tufts University School of Medicine and the Sackler School undertake research that is consistently rated among the highest in the nation for its impact on the advancement of medical science.
Closing the carbon loop
08.12.2016 | University of Pittsburgh
Newly discovered bacteria-binding protein in the intestine
08.12.2016 | University of Gothenburg
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
08.12.2016 | Life Sciences
08.12.2016 | Physics and Astronomy
08.12.2016 | Materials Sciences